I. Zaitsev

Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer.

H. Joensuu, T. Luukkaala, P. Kellokumpu-Lehtinen, 2012, Anticancer research.

Five‐year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry

R. Zukov, D. Sakaeva, P. Borisov, 2017, Clinical genitourinary cancer.

Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry

R. Zukov, A. Rolevich, S. Krasny, 2020, Cancer reports.